Synapse - Elsevier Science, Inc.

Elsevier Science, Inc.

SHERPA: Unknown

People

Shah
Geyer
Giralt
Palomba
Park
Perales
Sabbatini
Santomasso

Groups

Bone Marrow Transplant (4)
Center for Hematologic Malignancies (4)
Department of Medicine (4)
Hematologic Malignancies, Division of (4)
Survivorship Research (4)
Adult Leukemia (1)
Advanced Practice Providers (1)
Epidemiology and Biostatistics (1)
Executive Committee, Center for Hematologic Malignancies (1)
GDMT, Medicine (1)

Search Within

Results (4)

Export to EndNote / Excel

Real-world treatment patterns, healthcare resource utilization (HRU) and costs for relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Chimeric antigen receptor T-cell (CAR T) and monoclonal antibodies (MAB) therapies

Meeting Abstract

Feng, C.; Murphy, L.; Engel-Nitz, N.; Nguyen, A.; Patel, A.; DuCharme, M.; Fu, C.; Shah, G.
Value in Health (2023)

Fulltext@MSK | Save

Resource utilization within 30 days of car T cells for hematologic malignancies

Meeting Abstract

Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
Value in Health (2019)

Fulltext@MSK | Save

Enrollment patterns for hospice and cost of end-of-life care among elderly patients with diffuse large B-cell lymphoma: A SEER-Medicare analysis

Meeting Abstract

Kumar, A. J.; Winn, A.; Shah, G. L.; Lin, P.; Parsons, S. K.
Value in Health (2017)

Fulltext@MSK | Save

Cost-effectiveness of rituximab-based chemotherapy combinations for the intial therapy of follicular lymphoma

Meeting Abstract

Shah, G.; Winn, A.; Kumar, A.; Lin, P.; Parsons, S.
Value in Health (2017)

Fulltext@MSK | Save

Elsevier Science, Inc.

People

Groups

Results (4)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Elsevier Science, Inc. – authorized name for: